Robyn Karnauskas’s biotech blue skies have turned dark and stormy.

During the biotech boom-boom years, Citi’s large-cap biotech analyst earned a reputation for being eternally sunny. To Karnauskas, every drug was a blockbuster. Buy ratings were bountiful. Price targets moved in only one direction: up.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Wow – Porges writes. “We don’t see this uncertainty lifting in 2018, and possibly not ever.” Should I keep my subscription?

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy